+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genfit - logo

GENFIT is a biopharmaceutical company that focuses on developing diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. Its lead pipeline product elafibranor (GFT505) has recently completed a positive Phase 2b study in NASH (Non-Alcoholic Steato-Hepatitis). Genfit SA was founded in 1999 and is headquartered in Loos, France.

From
From
From
From
From
Nonalcoholic Steatohepatitis (NASH): Update Bulletin - Product Thumbnail Image

Nonalcoholic Steatohepatitis (NASH): Update Bulletin

  • Newsletter
  • December 2023
  • Global
From
NASH Treatment & Therapeutics Market Report 2023-2033 - Product Thumbnail Image

NASH Treatment & Therapeutics Market Report 2023-2033

  • Report
  • July 2023
  • 224 Pages
  • Global
From
From
From
Non-Alcoholic Steatohepatitis (NASH) - Global Clinical Trials Review, 2022 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Global Clinical Trials Review, 2022

  • Clinical Trials
  • January 2022
  • 561 Pages
  • Global
From
Competitor Landscape: Non-alcoholic Steatohepatitis (NASH) - Product Thumbnail Image

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

  • Report
  • November 2018
  • 52 Pages
  • Global
From
Global Primary Biliary Cholangitis Therapeutics Market 2024-2028 - Product Thumbnail Image

Global Primary Biliary Cholangitis Therapeutics Market 2024-2028

  • Report
  • November 2023
  • 151 Pages
  • Global
From
Global Non-alcoholic Steatohepatitis Market 2023-2027 - Product Thumbnail Image

Global Non-alcoholic Steatohepatitis Market 2023-2027

  • Report
  • August 2023
  • 146 Pages
  • Global
From
From
From
Loading Indicator